Prominent cancer centers expand portfolio of patient-centric treatment solutions with Xoft’s innovative, painless, scar-free solution
NASHUA, N.H., Dec. 12, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients with non-melanoma skin cancer (NMSC), including individuals precluded from surgery or those seeking a non-invasive option, will now have access to a proven alternative that has successfully treated more than 10,000 individuals worldwide.
“We are pleased to provide our community with the most advanced and targeted cancer care that meets the needs of each and every patient,” said Dr. May Lin Tao, Medical Director of Santa Clarita Radiation Therapy Center.
“Adding Xoft to our infrastructure expands our clinical tools which help patients achieve similar low rates of recurrence with excellent cosmetic outcomes compared to Mohs surgery – all with virtually no downtime,” said Dr. Marc Botnick, Medical Director of Sherman Oaks Radiation Therapy Center.
The Xoft technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation directly to the lesion, reducing the risk of damage to surrounding healthy tissue. The mobile system can be easily maneuvered from room-to-room, while minimal shielding requirements enable clinicians to deliver treatment in a standard exam room, offering a highly-efficient, flexible solution.
Appropriate candidates include NMSC patients with lesions in anatomically challenging locations such as the ears, nose, scalp, neck, shin, and elbows, as well as those with wound healing challenges, individuals taking anticoagulants, and patients with medical comorbidities that may prohibit them from surgery.
“A growing body of positive clinical research underscores the valuable benefits Xoft presents to both providers and patients seeking a non-invasive treatment option – reducing practice overhead and fostering provider collaboration, while also delivering a positive and personalized patient experience,” said Ken Ferry, CEO of iCAD. “We are thrilled to partner with one of the nation’s leading radiation oncology networks to tackle the growing NMSC epidemic and provide unprecedented access to our advanced treatment option.”
The Xoft System is cleared by the U.S. Food and Drug Administration, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer, and gynecological cancers.
ABOUT ICAD, INC
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
ABOUT SANTA CLARITA AND SHERMAN OAKS RADIATION THERAPY CENTERS, PART OF THE US ONCOLOGY NETWORK
Santa Clarita Radiation Therapy Center, of Valencia, CA and Sherman Oaks Radiation Therapy Center, of Sherman Oaks, CA are part of The US Oncology Network, which has more than 1,400 affiliated physicians with expertise in medical oncology, hematology, radiation oncology, gynecologic oncology, urology, oncology surgery and other specialties at more than 400 sites of care in 26 states, treating over 1.1 million patients annually. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for practices navigating today’s challenging healthcare landscape. The Network is supported by McKesson Specialty Health, an industry leader in solutions that empower the community patient care delivery system to advance the science, technology and quality of care.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Erin Bocherer, (855) 300-8209
Jeremy Feffer, (917) 749-1494